At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...

Cigna's Evernorth Health Services said on Wednesday its actions will enhance transparency about the company's negotiations.

An arbitrator has determined Prime Therapeutics violated federal and state antitrust laws against the AIDS Healthcare ...

It’s the latest step from pharmacy benefit managers to respond to relentless criticism from politicians and regulators over ...

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for ...

Carl Schmid, executive director of the HIV+Hepatitis Policy Institute in Washington, D.C., talks about the problems associated with generic HIV PrEP drug markups and potential ways to fix it.

As the 119th Congress convenes, policymakers have a historic opportunity to lower prescription drug prices for Americans. As ...

The FTC's first report drew a strong response from the PBM sector, with lawsuits filed in both directions. The FTC has accused the big three of operating a "perverse drug rebate system," while the ...

The lawsuit – which has been anticipated since the FTC published a damning report on the PBM sector in July – names CVS Health's Caremark, UnitedHealth Group's Optum, and Cigna's Express ...